Compounds of unstable DP IV-inhibitors

Details Compounds of unstable DP IV-inhibitors Compounds of unstable DP IV-inhibitors

2006-05-30

2006-05-30

Weber, Jon (Department: 1653)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S019300, C514S085000, C514S089000, C514S222200, C435S219000, C530S330000, C530S331000, C530S335000, C530S338000, C530S344000

Reexamination Certificate

active

07053055

ABSTRACT:
Novel compounds of unstable inhibitors of the serine peptidase dipeptidyl peptidase IV, are used in the treatment of various disorders, especially of metabolic disorders. The compounds can be used in the treatment of impaired glucose tolerance, glucosuria, hyperlipidaemia, metabolic acidoses, diabetes mellitus, diabetic neuropathy and nephropathy.

REFERENCES:
patent: 2961377 (1960-11-01), Shapiro et al.
patent: 3174901 (1965-03-01), Sterne
patent: 3879541 (1975-04-01), Kabbe et al.
patent: 3960949 (1976-06-01), Ahrens et al.
patent: 4028402 (1977-06-01), Fischer et al.
patent: 4935493 (1990-06-01), Bachovchin et al.
patent: 5433955 (1995-07-01), Bredehorst et al.
patent: 5462928 (1995-10-01), Bachovchin et al.
patent: 5512549 (1996-04-01), Chen et al.
patent: 5543396 (1996-08-01), Powers et al.
patent: 5614379 (1997-03-01), MacKellar
patent: 5624894 (1997-04-01), Bodor
patent: 5939560 (1999-08-01), Jenkins et al.
patent: 6006753 (1999-12-01), Efendic
patent: 25 42598 (1974-10-01), None
patent: 25 42 598 (1976-04-01), None
patent: 296 075 (1991-11-01), None
patent: 296 075 (1991-11-01), None
patent: 19616486 (1997-10-01), None
patent: 0 658 568 (1994-12-01), None
patent: 0 658 568 (1995-06-01), None
patent: 0 708 179 (1995-10-01), None
patent: 0 708 179 (1996-04-01), None
patent: 0 995 440 (2000-04-01), None
patent: 2085665 (1971-03-01), None
patent: 2 085 665 (1971-12-01), None
patent: 2696740 (1992-10-01), None
patent: 2 696 740 (1994-04-01), None
patent: 04-288098 (1992-10-01), None
patent: 4334357 (1992-11-01), None
patent: 4334357 (1992-11-01), None
patent: WO 91/11457 (1991-08-01), None
patent: WO 91/16339 (1991-10-01), None
patent: WO 91/17767 (1991-11-01), None
patent: 9308259 (1993-04-01), None
patent: 9511689 (1995-05-01), None
patent: WO 95/15309 (1995-06-01), None
patent: WO 95/29691 (1995-11-01), None
patent: WO 97/40832 (1997-11-01), None
patent: 9745117 (1997-12-01), None
patent: WO 98/19998 (1998-05-01), None
patent: WO 98/22494 (1998-05-01), None
patent: WO 00/01849 (2000-01-01), None
patent: WO 00/53171 (2000-09-01), None
patent: WO 01/62266 (2001-08-01), None
Stryer (1975) Biochemistry, pp. 451-452 (W.H. Freeman and Company, San Francisco).
Wakselman, M., Nguyen, C., Mazaleyrat, J.-P., Callebaut, C., Krust, B., Hovanessian, A.G., Inhibition of HIV-1 infection of CD 26+ but not CD26-cells by a potent cyclopeptidic inhibitor of the DPP IV activity of CD 26. Abstract P 44 of the 24th European Peptide Symposium 1996.
Willms, B. et al., Gastric Emptying, Glucose Response, and Insulin Secretion after a Liquid Test Meal: Effects of Exogenous Glucagon-Like Peptide-1 (GLP-1)-(7-36) Amide in Type 2 (Noninsulin-Dependent) Diabetic Patients.JCEM81:327-332 (1996).
Campbell, I.W. New Antidiabetic Drugs, ed. C.J. Bailey & P.R. Flatt, Smith-Gordon, “Sulphonylureas and metformin: efficacy and inadequacy”. 3:33-51 (1990).
The Merck Index, 11thEdition, An Encyclopedia of Chemicals, Drugs, and Biologicals, 1996, p. 934.
Martindale The Extra Pharmacopoeia, 30thEdition, London Pharmaceutical Press, 1993, p. 1619.
Chemical Abstracts, vol. 115, No. 15, Oct. 14, 1991 Columbus, Ohio, US; abstract No. 149947q, Schoen Ekkehard et al: “Dipeptidyl peptidase IV in the immune system. Effects of specific enzyme inhibitors on activity of dipeptidyl peptidase IV and proliferation of human lymphocytes”.
Chemical Abstracts, vol. 126, No. 2, Jan. 13, 1997 Columbus, Ohio, US; abstract No. 16161j, Stoeckel A. et al: “Competitive inhibition of proline specific enzymes by amino acid thioxopyrrolidides and thiazolidides”.
Chemical Abstracts, vol. 118, No. 25, Jun. 21, 1993 Columbus, Ohio, US; abstract No. 255342k, Hosoda, et al, “Preparation of N-(heterocyclic Carbonyl) Amino Acids and Analogs as Prolyl Endopeptidase Inhibitors”, Nov. 1992.
Arai et al: “Synthesis of prolyl endopeptidase inhibitors and evaluation of their structure-activity relationships : invitro inhibition of prolyl endopeptidase from Canine Brain” Chemical and Pharmaceutical Bulletin., Bd. 41, No. 9, pp. 1583-1588.
Amasheh, S., et al., “Electrophysiological analysis of the function of the mammalian renal peptide transporter expressed in Xenopus Laevis oocytes”. J. Physiol. 504, 169-174 (1997).
Hoffmann et al.,Journal of Chromatography A, “Inhibition of dipeptidyl peptidase IV (DP IV) by anti-DP IV antibodies and non-substrate X-X-Pro- oligopeptides ascertained by capillary elctrophoresis”, 1995, 716:355-362.
Hendrick et al.,Metabolism—Clinical and Experimental, “Glucagon-like Peptide-I-(7-37) Suppresses Hyperglycemia in Rats”, Jan. 1993, 42(1): 1-6.
Nauck et al.,Diabetologia, “Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients”, 1993, 36: 741-744.
Gutniak et al.,Diabetes Care, “Subcutaneous Injection of the Incretin Hormone Glucagon-Like Peptide 1 Abolishes Postprandial Glycemia in NIDDM”, Sep. 1994, 17(9): 1039-1044.
Deacon et al.,Journal of Clinical Endocrinology and Metabolism, “Degradation of Glucagon-Like Peptide-1 by Human Plasma in Vitro Yields and N-Terminally Truncated Peptide That Is a Major Endogenous Metabolite in Vivo”, 1995, 80(3):952-957.
Pauly et al.,Metabolism, “Improved Glucose Tolerance in Rats Treated with the Dipeptidyl Peptidase IV (CD26) Inhibitor Ile-Thiazolidide”, 1999, 48(3): 385-389.
Thorens et al.,Diabetes, “Glucagon-Like Pepetide-I and the Control of Insulin Secretion in the Normal State and in NIDDM”, 1993, 42:1219-1225.
J. Lin et al.: “Inhibition of dipeptidyl peptidase IV by fluoroolefin-containing n-peptidyl-0-hydroxylamine peptidomimetics” Proceedings of the National Academy of Sciences of USA, Bd. 95, Nov. 1998, Seiten 14020-14024, XP002117450 Washington US Seite 14023, rechte Spalte, Absatz 3—Seite 14024, linke Spalte, Absatz 1.
Korom, S., Demeester, I., Stadlbauer, T.H.W., Chandraker, A., Schaub, M, Sayegh, M.H., Belyaev, A., Haemers, A., Scharpe, S., Kupiec-Weglinski, J.W., Inhibition of CD26/dipeptidyl peptidase IV activity in vivo prolongs cardiac allograft survival in rat recipients, Transplantation 63, 1495 (1997).
Tanka, S., Murakmi, T., Horikawa, H., Sugiura, M., Kawashima, K., Sugita, T., Suppression of arthritis by the inhibitors of dipeptidyl peptidase IV. Int. J. Immunopharmacol. 19, 15 (1997).
Mentlein, R., Dahms, P. Grandt, D., Kruger, R., proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV. Regul. Pept. 49, 133 (1993).
Wetzl, W., Wagner, T., Vogel, D., Demuth, H.-U., Balschun, D., Effects of the CLIP fragment ACTH 20-24 on the duration of REM sleep episodes. Neuropeptides, 31, 41 (1997).
The Merck Index, 12thEdition,An Encyclopedia of Chemicals, Drugs, and Biologicals, 1996, p. 1014.
Martindale The Extra Pharmacopoeia, 30thEdition, London Pharmaceutical Press, 1993, p. 36.
Durinx, C.; et al.; et al.; “Reference Values for Plasma Dipepidyl-Pepidase IV activity and their Association with Other Laboratory Parameters”.Clin Chem Lab Med 2001, Feb.; 39 (2) :155-9, 1 page.
Gossrau, R.; “Cytochemistry of Membrane Proteases”,Histochem J, Jul. 1985; 17 (7) :737-71, 1 page.
Hahn. T.; et al.; “Enzyme Histochemical Evidence for the Presence of Potential Blood Pressure Regulating Proteases in Cultured Villous Explants from Human First Trimester Pacentae”.Acta HistochemDec. 1993, 95 (2) :185-92, 1 page.
Heymann, E. et al., “Has Dipeptidyl Peptidase IV an Effect on Blood Pressure and Coagulation.”Klin Wochenschr, Jan. 1984, 2;62 (1) :2-10, 1 page.
Magyar, C.E. et al., “Proximal Tubule Na Transporter Responses are the same during Acute and Chronic Hypertension.”Am J. Physiol Renal Physiol, Aug. 2000; 279 (2) :F358-69, 1 page.
Papies, B. et al., “Isoenzyme (Lactate Dehydrogenase, Aspartate Aminotransferase) and Dipeptidyl Peptidase IV Activity Changes in Blood Plasma Likely Indicative of Organ

Affiliated with

Also associated with

Rating

Compounds of unstable DP IV-inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compounds of unstable DP IV-inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds of unstable DP IV-inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3634937